Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18825094 | 0.93 | HRH3 (0.34) | HRH3TP53CYP2D6GPR119TDP1 | |
| SCHEMBL1425929 | 0.93 | HRH3 (0.34) | HRH3TP53CYP2D6GPR119TDP1 | |
| SCHEMBL344785 | 0.89 | TP53 (0.32) | HRH3TP53GPR119TDP1 | |
| SCHEMBL1998545 | 0.89 | TP53 (0.32) | HRH3TP53GPR119TDP1 | |
| SCHEMBL2679564 | 0.89 | TP53 (0.32) | HRH3TP53GPR119TDP1 | |
| SCHEMBL1457027 | 0.85 | EPHX2 (0.40) | TDP1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5991039 | 0.84 | HRH3 (0.33) | HRH3GAA | |
| SCHEMBL485230 | 0.83 | CYP2C19 (0.36) | HRH3CYP2D6GPR119TSHRALDH1A1 | |
| SCHEMBL23211116 | 0.81 | TP53 (0.32) | TP53TDP1 | |
| SCHEMBL17181227 | 0.81 | HRH3 (0.30) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4384224-A1 | CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384223-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| CN-118019727-A | Methods for preparing NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-116969934-A | Pyrimido aromatic ring compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116669724-A | T-type calcium channel modulators and methods of use thereof | 普拉西斯精密医药公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2002074774-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1149579-A2 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-0946517-A1 | N-(IMIDAZOLYLBUTYL) BENZENESULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SYNTHELABO (FR) | 1999-10-06 | — | — | EP | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| WO-1998022443-A1 | N-(IMIDAZOLYLBUTYL) BENZENESULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION | SYNTHELABO (FR) | 1998-05-28 | — | — | WO | disclosed |
| WO-1997049698-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| CN-1164232-A | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LTD (GB) | 1997-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | HRH3 3531/4885TP53 1488/4885CYP2D6 1140/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | HRH3 2144/4885TP53 3697/4885CYP2D6 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.